Survival in hard-to-treat myeloma extended with Elrexfio treatment
Pfizer’s Elrexfio (elranatamab) extends the lives of adults with relapsed or…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
First RR multiple myeloma patient treated with ABBV-383
A Phase 3 clinical trial evaluating the safety and…
CAR T-cell therapy Carvykti shows promise in early myeloma
A single infusion of the CAR T-cell therapy…
Blenrep lowers risk of disease progression vs. bortezomib in trial
GSK‘s Blenrep (belantamab mafodotin) cut the risk of…
Sarclisa under FDA priority review as first-line myeloma therapy
The U.S. Food and Drug Administration (FDA) has granted…
Bortezomib dosing once a week safer than twice a week: Study
Once-weekly induction therapy with bortezomib is as efficient as…
